About IBIGEN
IBIGEN is a company based in Aprilia (Italy) founded in 1970. IBIGEN offers products and services including Injectable Antibiotics and Gastroenterology Treatments.
- Headquarter Aprilia, Italy
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ibi-lorenzini.it/en
- Social LinkedIn
- Legal Name Istituto Biochimico Italiano Giovanni Lorenzini S.P.A
- Latest Funding Round$727.6K (USD), Grant
Jan 2017
- Investors
Products & Services of IBIGEN
IBIGEN offers a comprehensive portfolio of products and services, including Injectable Antibiotics and Gastroenterology Treatments.
Injectable antibiotics, including penicillins and cephalosporins, are produced and distributed for hospital use
Products for gastrointestinal conditions, such as those addressing constipation and hepatopathies, are developed and supplied
Funding Insights of IBIGEN
- Total Rounds 1
- Last Round Grant — $727,603
- First Round $727,603
(Jan 2017)
- Investors Count 1
All 1 funding rounds of IBIGEN with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $727,603 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in IBIGEN
IBIGEN has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for IBIGEN
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IBIGEN
11 people are tracked at IBIGEN (5 in leadership, 6 in team).
| Name | Role | Group |
|---|---|---|
Andrea Baiocchi | General Manager | Leadership |
Nicola Blundo | CFO | Leadership |
Francesca Rubino | Hr Director | Leadership |
Khevenhüller Johannes | CEO | Leadership |
Vincenzo Rossi | Senior Quality Director & QP | Leadership |
Antonia de Magistris | Addetto Servizio Prevenzione E Sicurezza | Team |
Elisa Ricchiuto | QC Manager | Team |
Francesco Riccioli | Controller | Team |
Cinzia Lucconi | QA Compliance Manager | Team |
Daniele M. | System Management & ICT Automation | Team |
Daniela Lupidi | QA Manager | Team |
Complete people profiles for IBIGEN
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IBIGEN
2 dated milestones of IBIGEN across 47 years, from founding to its latest funding, stage changes and deals.
- Founded IBIGEN is founded.
- Funding First funding round of $728K.
Web traffic of IBIGEN
The website of IBIGEN (ibi-lorenzini.it) receives about 5.4K visits a month and ranks #2,714,888 among all websites worldwide, #3,674 in Biotechnology and Pharmaceuticals.
- Monthly visits5.4K
▲ 57.9% vs previous month
- Unique visitors1.6K
per month
- Global rank#2,714,888
among all websites
- Category rank#3,674
Health · Biotechnology and Pharmaceuticals
- Bounce rate29%
- Pages per visit8.7
- Average visit6 min 36 sec
- DevicesDesktop 10% · Mobile 90%
Websites whose visitors overlap most with IBIGEN. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| contentgroup.it | 100% | – | – | View details | |
| ofi.it | 100% | 2.5K | #9,486,814 | View details | |
| specialspa.it | 100% | – | – | View details |
Similar companies to IBIGEN
10 companies that operate in the same segment as IBIGEN (Traditional Health & Nutrition), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | – | USD 3.02 B | 8,300 | |
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | – | USD 5.1 B | 13,500 | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | Petah Tikva, Central District, Israel | USD 500 M | USD 18.74 B | 51,792 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | – | USD 508.93 M | 5,180 | |
Pharmaceutical products are developed and marketed globally. | 2009 | Montville, New Jersey, United States | USD 155.92 M | – | – | |
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | – | USD 6.21 B | 25,870 | |
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations | 1991 | Delhi, Delhi, India | USD 367.2 M | USD 1.52 B | 21,320 | |
Generics, biosimilars, APIs, and vaccines are manufactured by Wockhardt. | 1967 | Mumbai, Maharashtra, India | – | USD 353.53 M | 3,410 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about IBIGEN
IBIGEN was founded in 1970 and raised its 1st funding round 47 years after it was founded.
IBIGEN is headquartered in Aprilia, Italy. It is registered at Aprilia, Lazio, Italy.
IBIGEN was established in 1970 in Aprilia, Italy, as a provider in the pharmaceutical sector. Injectable products are manufactured and distributed by the company, focusing on solutions for medical applications. Operations are centered in Italy, with services extending to various European and international clients through established supply chains. The domain ibi-lorenzini.it is utilized for online presence and information dissemination.
IBIGEN offers Injectable Antibiotics and Gastroenterology Treatments.
IBIGEN has 1 investor. Key investors include European Union.
IBIGEN operates through Istituto Biochimico Italiano Giovanni Lorenzini S.P.A.